1. Koh AS, Tay WT, Teng THK, et al. A comprehensive population based characterization of heart failure with mid-range ejection fraction: Characteristics and outcomes in HFmrEF. Eur J Heart Fail. 2017;19(12):1624-34. doi:10.1002/ejhf.945.
2. Cleland JGF, Lyon AR, McDonagh T, McMurray JJV. The year in cardiology: heart failure Eur Heart J. 2020;41(12):1232-48. doi:10.1093/eurheartj/ehz949.
3. Lund LH, Claggett B, Liu J, Lam CS, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum: Candesartan across the ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-9. doi:10.1002/ejhf.1149.
4. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. doi:10.1002/ejhf.813.
5. Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017;38(25):1951-8. doi:10.1093/eurheartj/ehx181.
6. Шляхто Е. В., Недогода С.В., Конради А.О. и др. Концепция новых национальных клинических рекомендаций по ожирению. Российский кардиологический журнал. 2016;(4):7-13. doi:10.15829/1560-4071-2016-4-7-13.
7. Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121(2):237-44. doi:10.1161/CIRCULATIONAHA.109.887893.
8. Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e535-e578. doi:10.1161/CIR.0000000000000450.
9. Gentile F, Sciarrone P, Zamora E, et al. Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. Eur J Prev Cardiol. 2020;2047487320927610. doi:10.1177/2047487320927610.
10. Streng KW, Nauta JF, Hillege HL, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132-9. doi:10.1016/j.ijcard.2018.04.001.
11. Delepaul B, Robin G, Delmas C, et al. Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines? ESC Heart Fail. 2017;4(2):99-104. doi:10.1002/ehf2.12131.
12. Dadarlat-Pop A, Sitar-Taut A, Zdrenghea D, et al. Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure. Clin Interv Aging. 2020;15:547-56. doi:10.2147/CIA.S248158.
13. Singh M, Sethi A, Mishra AK, et al. Echocardiographic Imaging Challenges in Obesity: Guideline Recommendations and Limitations of Adjusting to Body Size. J Am Heart Assoc. 2020;9(2):e014609. doi:10.1161/JAHA.119.014609.
14. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
15. Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr. 2015;28(7):727-54. doi:10.1016/j.echo.2015.05.002.
16. Ситникова М.Ю., Лясникова Е.А., Юрченко А.В. и др. Результаты 3 лет работы Российского госпитального регистра хронической сердечной недостаточности (RUssian hoSpital Heart Failure Registry — RUS-HFR): взаимосвязь менеджмента и исходов у больных хронической сердечной недостаточностью. Кардиология. 2018;58(10S):9-19. doi:10.18087/cardio.2483.
17. Csige I, Ujvarosy D, Szabo Z, et al. The Impact of Obesity on the Cardiovascular System. J Diabetes Res. 2018;2018:3407306. doi:10.1155/2018/3407306.
18. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88(2):389-419. doi:10.1152/physrev.00017.2007.
19. Лебедев Д.А., Лясникова Е. А., Васильева А. А. и др. Молекулярный биомаркерный профиль хронической сердечной недостаточности с промежуточной и сохраненной фракцией выброса левого желудочка на фоне сахарного диабета 2 типа. Российский кардиологический журнал. 2020;25(10):3967. doi:10.15829/1560-4071-2020-3967.
20. Lebedev DA, Lyasnikova EA, Vasilyeva EY, et al. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis. J Diabetes Res. 2020;2020:6976153. doi:10.1155/2020/6976153.
21. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.
22. Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123(5):614-29. doi:10.1161/CIRCRESAHA118.312706.
23. Reinmann M, Meyer P. B-type natriuretic peptide and obesity in heart failure: a mysterious but important association in clinical practice. Cardiovasc Med. 2020;23:w02095. doi:10.4414/cvm.2020.02095.
24. Clerico A, Zaninotto M, Passino C, et al. Obese phenotype and natriuretic peptides in patients with heart failure with preserved ejection fraction. Clin Chem Lab Med. 2018;56(7):1015-25. doi:10.1515/cclm-2017-0840.
25. Obokata M, Reddy YNV, Pislaru SV, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6-19. doi:10.1161/CIRCULATIONAHA.116.026807.
26. Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611-7. doi:10.1016/j.ijcard.2014.08.007.
27. Luchner A, Schunkert H. Interactions between the sympathetic nervous system and the cardiac natriuretic peptide system. Cardiovasc Res. 2004;63(3):443-9. doi:10.1016/j.cardiores.2004.05.004.
28. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-317. doi:10.1093/eurheartj/ehz641.
29. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. doi:10.1002/ejhf.1494.
30. Reddy YNV, Carter RE, Obokata M, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. doi:10.1161/CIRCULATIONAHA.118.034646.
31. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.
32. Kim H, Jun DW, Cho YK, et al. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction. Echocardiography. 2008;25(9):961-7. doi:10.1111/j.1540-8175.2008.00717.